#Anakinra for severe forms of #COVID-19: a cohort study

Coronaviruses can induce the production of interleukin (IL)-1Ξ², IL-6, tumour necrosis factor, and other cytokines implicated in autoinflammatory disorders. It has been postulated that anakinra, a recombinant IL-1 receptor antagonist, might help to neutralise the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related hyperinflammatory state, which is considered to be one cause of acute respiratory distress …

Continue reading #Anakinra for severe forms of #COVID-19: a cohort study

Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic #fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study

AMP kinase (AMPK) is an energy sensor implicated in regulation of lipid metabolism, inflammation, and insulin sensitivity. We aimed to assess efficacy and safety of PXL770, a novel direct AMPK activator, in patients with non-alcoholic fatty liver disease (NAFLD). MethodsSTAMP-NAFLD, a randomised, double-blind, placebo-controlled phase 2a study, was done across 15 US clinical sites. Patients …

Continue reading Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic #fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study